• ABPI Website
  • Media
  • ABPI statement on intellectual property rights for COVID vaccines
ABPI statement on intellectual property rights for COVID vaccines

The United States has said it will support a proposal to waive intellectual property and patents on COVID-19 vaccines.

We share the goal of getting COVID-19 vaccines to the people who need them as fast as possible, but waiving IP is not the solution. Richard Torbett

In response, Richard Torbett, Chief Executive of the ABPI, said:

"Companies have been working with international partners for months to scale up the supply of vaccines, voluntarily licensing and transferring technology where it is safe to do so. The real challenges are a lack of advanced manufacturing skills and critical raw materials.

"Globally we must now focus on sharing excess doses of vaccines, maintaining the free movement of raw materials and properly funding COVAX - all of which the UK government has committed to doing.

"We share the goal of getting COVID-19 vaccines to the people who need them as fast as possible, but waiving IP is not the solution. In the short term, it will hinder vaccine scale-up and in the long term, significantly impact global investment into new vaccines and medicines, including for future pandemics."

TAGS
  • Intellectual Property

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.